Silvia Fargion

Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

Vlad Ratziu, Stephen A. Harrison, Sven Francque et al. · Gastroenterology · 2016 · 1K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes

Anna Ludovica Fracanzani, Luca Valenti, Elisabetta Bugianesi et al. · Hepatology · 2008 · 702 citations

Medicine, Internal Medicine, Pathology +17

The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent

Rosellina Margherita Mancina, Paola Dongiovanni, Salvatore Petta et al. · Gastroenterology · 2016 · 664 citations · Full text

Medicine, Internal Medicine, Epidemiology +9

Homozygosity for the patatin‐like phospholipase‐3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease†

Luca Valenti, Ahmad Al‐Serri, Ann K. Daly et al. · Hepatology · 2010 · 649 citations · Full text

Medicine, Genetics, Molecular Genetics +13

Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease

Paola Dongiovanni, Salvatore Petta, Cristina Maglio et al. · Hepatology · 2014 · 529 citations · Full text

Medicine, Molecular Genetics, Molecular Medicine +17